XML 44 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Acquisition (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Nov. 05, 2015
Jun. 24, 2015
Mar. 04, 2017
Jun. 03, 2017
Apr. 02, 2015
Final purchase price allocation          
Goodwill     $ 1,715,479 $ 1,715,479  
Pharmacy Services          
Final purchase price allocation          
Goodwill   $ 1,639,355      
Amount of goodwill deductible for tax purpose   $ 1,368,657      
6.125% senior notes due 2023          
Acquisition          
Principal amount of debt     $ 1,800,000 $ 1,800,000  
Debt instrument, stated interest rate (as a percent)     6.125% 6.125%  
EnvisionRx          
Acquisition          
Ownership interest (as a percent)   100.00%      
Stock consideration (in shares)   27,754      
Share price   $ 8.68      
Final purchase price          
Cash consideration $ 116,057 $ 1,882,211 $ 1,882,211    
Stock consideration   240,907 240,907    
Total     2,123,118    
Final purchase price allocation          
Cash and cash equivalents     103,834    
Accounts receivable     892,678    
Inventories     7,276    
Prepaid expenses and other current assets     13,386    
Total current assets     1,017,174    
Property and equipment     13,196    
Intangible assets(1)   646,600 646,600    
Goodwill     1,639,355    
Other assets     7,219    
Total assets acquired     3,323,544    
Accounts payable     491,672    
Reinsurance funds held     381,225    
Other current liabilities(2)     215,770    
Total current liabilities     1,088,667    
Other long term liabilities(3)     111,759    
Total liabilities assumed     1,200,426    
Net assets acquired     $ 2,123,118    
EnvisionRx | Trademarks          
Final purchase price allocation          
Estimated Fair Value of indefinite lived intangible assets   33,500      
EnvisionRx | Customer relationships          
Final purchase price allocation          
Estimated Fair Value of Finite lived intangible assets   $ 465,000      
Estimated Useful Life   17 years      
EnvisionRx | CMS license          
Final purchase price allocation          
Estimated Fair Value of Finite lived intangible assets   $ 57,500      
Estimated Useful Life   25 years      
EnvisionRx | Claims adjudication and other developed software          
Final purchase price allocation          
Estimated Fair Value of Finite lived intangible assets   $ 59,000      
Estimated Useful Life   7 years      
EnvisionRx | Trademarks          
Final purchase price allocation          
Estimated Fair Value of Finite lived intangible assets   $ 20,100      
Estimated Useful Life   10 years      
EnvisionRx | Backlog          
Final purchase price allocation          
Estimated Fair Value of Finite lived intangible assets   $ 11,500      
Estimated Useful Life   3 years      
EnvisionRx | 6.125% senior notes due 2023          
Acquisition          
Principal amount of debt         $ 1,800,000
Debt instrument, stated interest rate (as a percent)         6.125%